Overview

• The Series E round brought in $650 million from investors including ARK Invest, Founders Fund and Sequoia Capital.
• Proceeds will fund ongoing human clinical trials of its implantable brain-computer interface for patients with severe paralysis.
• The company has implanted its chip in five trial participants, enabling them to control computers and browse the internet with thought alone.
• In May, the U.S. Food and Drug Administration granted the device a breakthrough designation to expedite its development and review.
• Neuralink aims to restore independence for people with spinal cord injuries by translating neural signals into digital commands.